Viking Therapeutics Reports First Quarter 2017 Financial Results and Provides Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Viking Therapeutics (VKTX) Misses Q1 EPS by 6c
May 10, 2017 4:16 PM EDTViking Therapeutics (NASDAQ: VKTX) reported Q1 EPS of ($0.23), $0.06 worse than the analyst estimate of ($0.17).
At March 31, 2017, Viking held cash, cash equivalents and investments totaling $12.3 million. As of April 30, 2017, Viking had 23,925,425 shares of common stock outstanding.
For earnings history and earnings-related data on Viking Therapeutics (VKTX) click here.
... More